可溶性抑瘤因子2表达水平监测对儿童异基因造血干细胞移植后早期重度急性移植物抗宿主病的预测价值

The value of monitoring the expression level of soluble tumor suppressor factor 2 in predicting early severe acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation in children

目的:研究不同供者来源儿童异基因造血干细胞移植后监测外周血可溶性抑瘤因子2(soluble tumor suppressor factor 2,sST2)表达水平对早期重度急性移植物抗宿主病(acute graft-versus-host disease,aGVHD)发生的临床预测价值。方法:回顾性分析2020年1月至2022年5月在我院行allo-HSCT的44例患儿的临床资料,将移植后18例发生Ⅲ~Ⅳ度aGVHD的患儿作为观察组,其余26例患儿作为对照组,比较2组基线数据及患儿在移植前、移植后14天和21天sST2表达水平的差异。构建受试者工作特征曲线,根据sST2表达中位水平分为sST2高表达组和低表达组,比较2组患儿不同器官aGVHD的累积发生率。结果:观察组和对照组患儿移植前、移植后14天外周血sST2水平比较差异无统计学意义,观察组患儿移植后21天外周血sST2水平明显高于对照组,差异有统计学意义(P<0.001)。移植后21天sST2诊断Ⅲ~Ⅳ度aGVHD的受试者工作特征曲线下面积为0.842(95%CI 0.715~0.968),对应的特异度为96%,灵敏度为67%。根据移植后21天外周血sST2表达水平的中位数(71222.0 pg/mL),将患儿分为高sST2组(22例)和低sST2组(22例)。高sST2组Ⅲ~Ⅳ度aGVHD、2~4级肠道aGVHD、皮肤aGVHD发生率明显高于低sST2组(63.6%vs 18.2%,P=0.002;59.1%vs 13.6%,P=0.002;90.9%vs 63.6%,P=0.031);高sST2组上消化道或肝脏aGVHD发生率有高于低sST2组的趋势,但差异无统计学意义(40.9%vs 18.2%,P=0.099)。结论:血液病患儿不同供者来源异基因造血干细胞移植后21天外周血sST2表达水平升高有助于预测Ⅲ~Ⅳ度aGVHD的发生。外周血sST2有望成为异基因造血干细胞移植后重度aGVHD的生物标记物,仍需多中心、大样本进一步研究证实。

Objective: To investigate the clinical value of monitoring the expression level of soluble tumor suppressor factor 2(sST2)in peripheral blood after allogeneic hematopoietic stem cell transplantation(allo-HSCT)in children from different donors in predicting the occurrence of early severe acute graft-versus-host disease(aGVHD).Methods: The clinical data of 44 children who underwent allo-HSCT in our hospital from January 2020 to May 2022 were retrospectively analyzed.Eighteen children with gradeⅢ-ⅣaGVHD after transplantation were selected as the observation group,and the remaining 26 children were selected as the control group.The baseline data and sST2 expression levels before allo-HSCT,14 d and 21 d after allo-HSCT were compared between the two groups.The receiver operating characteristic curve was constructed.According to the median level of sST2 expression,the children were divided into a high sST2 expression group and a low sST2 expression group,and the cumulative incidence of aGVHD in different organs was compared between the two groups.Results: There was no significant difference in the level of peripheral blood sST2 before transplantation and 14 days after allo-HSCT between the observation group and the control group.The level of peripheral blood sST2 in the observation group was significantly higher than that in the control group 21 days after transplantation(P<0.001).The area under the receiver operating characteristic curve of sST2 for the diagnosis of gradeⅢ-ⅣaGVHD at 21 days after allo-HSCT was 0.842(95%CI 0.715-0.968),and the corresponding sensitivity was 96%,the specificity was 67%.The children were divided into high sST2 group(22 cases)and low sST2 group(22 cases)according to the median level of sST2(71222.0 pg/mL)in peripheral blood on day 21 after transplantation.The incidence of gradeⅢ-ⅣaGVHD,grade 2-4 intestinal aGVHD,and skin aGVHD in the high sST2 group was significantly higher than that in the low sST2 group(63.6%vs 18.2%,P=0.002;59.1%vs 13.6%,P=0.002;90.9%vs 63.6%,P=0.031).The incidence of upper gastrointestinal or hepatic aGVHD also tended to be higher than that in the low sST2 group,while there was no significant difference(40.9%vs 18.2%,P=0.099).Conclusion: The elevated expression of sST2 in peripheral blood of children with hematological diseases at 21 days after allo-HSCT from different donors is helpful to predict the occurrence ofⅢ-ⅣaGVHD.Peripheral blood sST2 is expected to be a biomarker for severe aGVHD after allo-HSCT,which still needs to be further confirmed by multi-center and larger sample studies.